Clearside Biomedical, Inc. (CLSD)
NASDAQ: CLSD · Real-Time Price · USD
0.9076
-0.0103 (-1.12%)
At close: Apr 1, 2025, 4:00 PM
0.9000
-0.0076 (-0.84%)
After-hours: Apr 1, 2025, 5:42 PM EDT
Clearside Biomedical Revenue
In the year 2024, Clearside Biomedical had annual revenue of $1.66M, down -79.77%. Clearside Biomedical had revenue of $306.00K in the quarter ending December 31, 2024, a decrease of -95.18%.
Revenue (ttm)
$1.66M
Revenue Growth
-79.77%
P/S Ratio
40.71
Revenue / Employee
$55,467
Employees
30
Market Cap
70.02M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.66M | -6.56M | -79.77% |
Dec 31, 2023 | 8.23M | 6.90M | 519.89% |
Dec 31, 2022 | 1.33M | -28.25M | -95.51% |
Dec 31, 2021 | 29.58M | 21.68M | 274.65% |
Dec 31, 2020 | 7.89M | 5.72M | 263.28% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
CLSD News
- 11 hours ago - Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 4 days ago - Clearside Biomedical, Inc. (CLSD) Q4 2024 Earnings Conference Call Transcript - Seeking Alpha
- 5 days ago - Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 8 days ago - Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting - GlobeNewsWire
- 12 days ago - Clearside Biomedical's Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit - GlobeNewsWire
- 20 days ago - Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025 - GlobeNewsWire
- 26 days ago - Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD - GlobeNewsWire
- 5 weeks ago - Clearside Biomedical's Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular Edema - GlobeNewsWire